This case report highlights the importance of recognizing potential pitfalls in HbA1c measurement errors and being vigilant in terms of discrepancies between HbA1c estimated from continuous glucose monitoring (CGM) and venous HbA1c measurements. The latter is especially relevant for physicians managing diabetes, as by 2025, 4,400 adults with insulin-treated type 2 diabetes are expected to start using CGM devices, many of whom will be monitored in primary care settings.